Isofol Medical has reported positive efficacy data from the currently ongoing phase I/II trial in colorectal cancer. The results follow from an extended analysis of patients that have been treated for 16 weeks with Modufolin as a first line treatment. The results are, in our view, promising, and gives support for forthcoming studies. Today's news will not result in any changes of our valuation of the company.